JP2025521082A - 安定化融合前ｈｍｐｖ融合タンパク質 - Google Patents

安定化融合前ｈｍｐｖ融合タンパク質 Download PDF

Info

Publication number
JP2025521082A
JP2025521082A JP2024566227A JP2024566227A JP2025521082A JP 2025521082 A JP2025521082 A JP 2025521082A JP 2024566227 A JP2024566227 A JP 2024566227A JP 2024566227 A JP2024566227 A JP 2024566227A JP 2025521082 A JP2025521082 A JP 2025521082A
Authority
JP
Japan
Prior art keywords
protein
amino acid
hmpv
acid residue
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521082A5 (cg-RX-API-DMAC7.html
Inventor
ランゲディク，ヨハネス・ペトラス・マリア
バッカーズ，マーク・ヨハネス・ゲラルダス
リッチェル，ティーナ
ユラゼク，ヤロスラフ
Original Assignee
エムエスディー インターナショナル ビジネス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムエスディー インターナショナル ビジネス ゲーエムベーハー filed Critical エムエスディー インターナショナル ビジネス ゲーエムベーハー
Publication of JP2025521082A publication Critical patent/JP2025521082A/ja
Publication of JP2025521082A5 publication Critical patent/JP2025521082A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024566227A 2022-05-12 2023-05-11 安定化融合前ｈｍｐｖ融合タンパク質 Pending JP2025521082A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
EP22173131.8 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (2)

Publication Number Publication Date
JP2025521082A true JP2025521082A (ja) 2025-07-08
JP2025521082A5 JP2025521082A5 (cg-RX-API-DMAC7.html) 2026-07-08

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566227A Pending JP2025521082A (ja) 2022-05-12 2023-05-11 安定化融合前ｈｍｐｖ融合タンパク質

Country Status (16)

Country Link
EP (1) EP4522209A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025521082A (cg-RX-API-DMAC7.html)
KR (1) KR20250010642A (cg-RX-API-DMAC7.html)
CN (1) CN119562826A (cg-RX-API-DMAC7.html)
AU (1) AU2023269241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253332A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003418A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015386A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240493A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000230A (cg-RX-API-DMAC7.html)
GE (1) GEAP202516650A (cg-RX-API-DMAC7.html)
IL (1) IL316911A (cg-RX-API-DMAC7.html)
JO (1) JOP20240256A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013959A (cg-RX-API-DMAC7.html)
PE (1) PE20251395A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023217988A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
CN118359709A (zh) * 2019-05-21 2024-07-19 佐治亚大学研究基金会有限公司 结合人类偏肺病毒融合蛋白的抗体及其用途
IL320367A (en) * 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins

Also Published As

Publication number Publication date
KR20250010642A (ko) 2025-01-21
DOP2024000230A (es) 2025-02-16
CN119562826A (zh) 2025-03-04
JOP20240256A1 (ar) 2024-11-11
PE20251395A1 (es) 2025-05-22
WO2023217988A1 (en) 2023-11-16
CA3253332A1 (en) 2023-11-16
AU2023269241A1 (en) 2024-11-21
IL316911A (en) 2025-01-01
CL2024003418A1 (es) 2025-08-01
CR20240493A (es) 2025-01-29
EP4522209A1 (en) 2025-03-19
GEAP202516650A (en) 2025-03-10
MX2024013959A (es) 2025-02-10
CO2024015386A2 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
US10967057B2 (en) Zika viral antigen constructs
JP7362819B2 (ja) 安定化された可溶性融合前ｒｓｖ ｆタンパク質
US20230242593A1 (en) Zika viral antigen constructs
KR20250010642A (ko) 안정화된 융합-전 hmpv 융합 단백질
US12011477B2 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
US20230364219A1 (en) Sars cov-2 spike protein construct
JP2023525785A (ja) 安定化コロナウイルススパイクタンパク質をコードするｒｎａレプリコン
JP2023524860A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン
EP4448802A1 (en) Stabilized pre-fusion hmpv fusion proteins
WO2013142809A1 (en) Baculovirus-based enterovirus 71 vlp as a vaccine
WO2022157153A2 (en) Therapeutic viral vaccine
CN116688113A (zh) 核酸疫苗
HK40073646A (en) Zika viral antigen constructs
WO2023047348A1 (en) Stabilized corona virus spike protein fusion proteins
OA18878A (en) Vaccine against RSV

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260629